Potentially Inappropriate Prescribing and Potential Clinically Significant Drug-Drug Interactions in Older Outpatients: Is There Any Association?

被引:12
|
作者
Cvetkovic, Zorica [1 ]
Peric, Aneta [2 ]
Dobric, Silva [3 ]
机构
[1] Mil Pharm Slavija, Cent Pharm Storage, Dept Mil Hlth, Belgrade 11000, Serbia
[2] Mil Med Acad, Dept Pharm, Belgrade 11000, Serbia
[3] Univ Def, Mil Med Acad, Fac Med, Belgrade 11000, Serbia
来源
MEDICINA-LITHUANIA | 2019年 / 55卷 / 07期
关键词
drug-drug interactions; older patients; outpatients; potentially inappropriate prescribing; STOPP criteria; ANGIOTENSIN-RECEPTOR BLOCKERS; STOPP/START CRITERIA; ELDERLY-PATIENTS; COST OUTCOMES; PEOPLE; PREVALENCE; INHIBITORS; ADULTS; POPULATION;
D O I
10.3390/medicina55070332
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: The purpose of the study was to determine the prevalence rate of potentially inappropriate prescribing ( PIP), by using the Screening Tool of Older Person's potentially inappropriate Prescriptions ( STOPP) criteria in older outpatients, and its association with potential clinically significant drug-drug interactions ( csDDIs). Materials and Methods: A cross-sectional study included 248 outpatients >= 65 years old divided into two groups depending on the presence of csDDIs. For estimating the clinical significance of csDDIs we used Medscape 0 s " Drug Interaction Checker". We applied the thirty PIP indicators from the STOPP criteria. Results: The presence of PIP ( 25.00%; all patients) was significantly higher in the group with potential csDDIs compared to the other group ( 43 vs. 19, respectively; Chi-square test, chi(2) = 9.947; p < 0.01). The most common PIP included the inappropriate use of proton pump inhibitors, long acting benzodiazepines, usage of thiazide diuretic in patients with gout, and duplication of therapeutic class. Patients with potential csDDIs had 43 potentially inappropriate medications ( PIMs) prescribed. Out of this number, 12 ( 27.91%) PIMs were identified to participate in potential csDDIs. There was a correlation between the number of medications prescribed and the number of PIMs (rho = 0.297; p < 0.01) and between the number of PIPs and the number of potential csDDIs (rho = 0.170; p < 0.01). Conclusions: Older outpatients with potential csDDIs in relation to those with no potential csDDIs had significantly more prescribed drugs in total as well as inappropriate drugs. Almost 30% of these PIMs were included in potential csDDIs.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Potentially inappropriate drug prescribing among first-visit elderly outpatients in Taiwan
    Chang, CM
    Liu, PYY
    Yang, YHK
    Yang, YC
    Wu, CF
    Lu, FH
    PHARMACOTHERAPY, 2004, 24 (07): : 848 - 855
  • [42] Prevalence and factors associated with potential clinically significant drug-drug interactions in patients with cardiovascular diseases at hospital admission
    Marovic, Iva
    Udovicic, Mario
    Rudan, Diana
    Manola, Sime
    Samardzic, Ivana
    Vrca, Vesna Bacic
    Hadziabdic, Maja Ortner
    Marinovic, Ivana
    ACTA PHARMACEUTICA, 2024, 74 (04) : 693 - 708
  • [43] Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature
    Hodge, Daryl
    Hodel, Eva Maria
    Hughes, Elen
    Hazenberg, Phoebe
    Granana Castillo, Sandra
    Gibbons, Sara
    Wang, Duolao
    Marra, Fiona
    Marzolini, Catia
    Back, David
    Khoo, Saye
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2023, 92 (02) : 97 - 105
  • [44] Potentially inappropriate medications and drug-drug interactions in home-dwelling people with mild dementia
    Oesterhus, Ragnhild
    Aarsland, Dag
    Soennesyn, Hogne
    Rongve, Arvid
    Selbaek, Geir
    Kjosavik, Svein R.
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2017, 32 (02) : 183 - 192
  • [45] Prevalence of potential drug-drug interactions in outpatients on treatment with parenteral antineoplastic drugs
    Castro-Manzanares, M.
    do Pazo-Oubina, F.
    Rodriguez-Rincon, R. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (06) : 1429 - 1433
  • [46] Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants
    Lange, Nicholas W.
    Salerno, David M.
    Jennings, Douglas L.
    Choe, Jason
    Hedvat, Jessica
    Kovac, Danielle
    Scheffert, Jenna
    Shertel, Tara
    Ratner, Lloyd E.
    Brown, Robert S., Jr.
    Pereira, Marcus R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 (07) : 1925 - 1926
  • [47] Prevalence of Clinically Significant Drug-Drug Interactions Across US Children's Hospitals
    Antoon, James W.
    Hall, Matt
    Herndon, Alison
    Carroll, Alison
    Ngo, My-linh
    Freundlich, Katherine L.
    Stassun, Justine C.
    Frost, Patricia
    Johnson, David P.
    Chokshi, Swati B.
    Brown, Charlotte M.
    Browning, Whitney L.
    Feinstein, James A.
    Grijalva, Carlos G.
    Williams, Derek J.
    PEDIATRICS, 2020, 146 (05)
  • [48] Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder
    Schoretsanitis, Georgios
    de Leon, Jose
    Eap, Chin B.
    Kane, John M.
    Paulzen, Michael
    CNS DRUGS, 2019, 33 (12) : 1201 - 1222
  • [49] Factors associated with clinically relevant drug-drug interactions with statins in outpatients with coronary artery disease
    Domingos dos Santos, Jessica Nathalia
    Souza Groia Veloso, Ronara Camila
    Tinoco, Marlon Silva
    Moreira Reis, Adriano Max
    MUNDO DA SAUDE, 2020, 44 (01): : 506 - 514
  • [50] The “iatrogenic triad”: polypharmacy, drug–drug interactions, and potentially inappropriate medications in older adults
    Priscila Horta Novaes
    Danielle Teles da Cruz
    Alessandra Lamas Granero Lucchetti
    Isabel Cristina Gonçalves Leite
    Giancarlo Lucchetti
    International Journal of Clinical Pharmacy, 2017, 39 : 818 - 825